Profile Response Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Molecular Profile ERBB3 over exp
Therapy Patritumab
Indication/Tumor Type prostate cancer
Response Type predicted - sensitive


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ERBB3 over exp prostate cancer predicted - sensitive Patritumab Preclinical - Pdx & cell culture Actionable In a preclinical study, Patritumab (U3-1287) treatment decreased viability of patient-derived prostate cancer cells with high ERBB3 (HER3) expression in culture but did not inhibit tumor growth in a patient-derived xenograft (PDX) model, and did not demonstrate anti-tumor activity in cell lines with low ERBB3 (HER3) expression (PMID: 34753775). 34753775
PubMed Id Reference Title Details
(34753775) HER3 Is an Actionable Target in Advanced Prostate Cancer. Full reference...